Amarin Corporation plc announced that Murray W. Stewart, D.M., F.R.C.P., has been appointed to the company's Board of Directors. Following the appointment of Dr. Stewart, the Amarin Board will be made up of approximately 70% of new independent directors who were named to the Board over the last 12 months. Dr. Stewart is a physician by training and brings more than 30 years of cardiometabolic academic and industry experience to the Amarin Board of Directors.

As a Consultant Physician with the National Health Service (NHS) in the United Kingdom (UK), Dr. Stewart led clinical teams in diabetes and general medicine. During his 18-year tenure at GlaxoSmithKline (GSK), Dr. Stewart held multiple roles, including Chief Medical Officer, Clinical Head of the Biopharma Unit and Therapy Area Head for Metabolic and Cardiovascular diseases. Recently, Dr. Stewart was Chief Medical Officer at Rhythm Pharmaceuticals where he was responsible for the development of new medicines and transforming the care for patients with rare genetic diseases of Obesity.

Dr. Stewart holds a Bachelor of Medicine and a Doctor of Medicine from Southampton Medical School in the UK and is a Fellow of the Royal College of Physicians.